サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1757508

デジタル・バイオマニュファクチャリングの世界市場

Digital Biomanufacturing

出版日
ページ情報
英文 341 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.81円
デジタル・バイオマニュファクチャリングの世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 341 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

デジタル・バイオマニュファクチャリングの世界市場は2030年までに391億米ドルに到達

2024年に182億米ドルと推定されるデジタル・バイオマニュファクチャリングの世界市場は、2024年から2030年にかけてCAGR 13.6%で成長し、2030年には391億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるソフトウェア・オファリングは、CAGR 15.1％を記録し、分析期間終了時には297億米ドルに達すると予測されます。ハードウェア提供セグメントの成長率は、分析期間でCAGR 9.6％と推定されます。

米国市場は50億米ドルと推定、中国はCAGR18.5％で成長予測

米国のデジタル・バイオマニュファクチャリング市場は2024年に50億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに84億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは18.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.8%と12.3%と予測されています。欧州では、ドイツがCAGR 10.8%で成長すると予測されています。

世界のデジタル・バイオマニュファクチャリング市場- 主要動向と促進要因のまとめ

バイオマニュファクチャリングにおけるデジタル化シフトの原動力は？

デジタル・バイオマニュファクチャリングは、生物学的生産システムにデータ駆動技術を統合し、バイオ医薬品およびバイオテクノロジー製造プロセス全体の効率性、柔軟性、品質を向上させることを表しています。伝統的にバッチベースの手作業に依存してきたバイオ製造業界は、現在、高度なプロセス制御、予測分析、人工知能、機械学習などのデジタルツールを採用し、業務の近代化と最適化を図っています。これらのテクノロジーは、リアルタイムのモニタリング、プロセスパラメーターの動的制御、意思決定の自動化を可能にし、最終的に歩留まりを向上させ、ばらつきを減らし、製品リリースを加速させる。

デジタル化の推進は、個別化医療、遺伝子治療、バイオシミラーなど、生産スケジュールと品質管理が極めて重要な分野では特に重要です。このようなリスクの高いアプリケーションでは、デジタルツールによって、バッチサイズ、製品タイプ、規制上の期待の変化に製造が迅速に対応できるようになります。上流から下流までのプロセスを通じて大規模なデータセットを取得し、モデル化し、それに基づいて行動する能力は、バイオ製造業を反応的な業務から予測的で適応的な業務へと移行させる重要な転換点となります。

先端技術はどのようにデジタル・バイオマニュファクチャリング革命の原動力となっているのか？

デジタル・バイオマニュファクチャリングのバックボーンは、プロセス分析技術（PAT）、デジタルツイン、クラウドコンピューティング、AI対応バイオプロセス制御システムなどのテクノロジーにあります。PATツールは、主要な品質属性の連続的なインライン測定を可能にし、バッチ後のテストに頼るのではなく、生産中にプロセスパラメーターを動的に調整することを可能にします。デジタル・ツイン（物理的なバイオプロセスの仮想レプリカ）は、シナリオをシミュレートし、結果を予測し、実施前にシステム性能を最適化することができるため、リスクを低減し、コストのかかるダウンタイムを最小限に抑えることができます。

機械学習アルゴリズムは、バイオプロセスのデータに適用され、細胞増殖、製品力価、汚染リスクを予測し、先手を打った介入を可能にしています。クラウドベースのプラットフォームとエッジコンピューティングは、施設間でのリアルタイムのデータ共有を容易にし、世界なコラボレーションと集中管理をより身近なものにしています。ロボット工学とスマートセンサーは、培地調製、細胞株開発、精製などの作業の自動化も可能にし、再現性、拡張性、コンプライアンスの向上に貢献しています。これらの進歩は単なる技術的なアップグレードではなく、生物製剤の生産、検証、世界の流通のあり方を変えつつあります。

市場導入を促進するアプリケーションと利害関係者とは？

デジタル・バイオマニュファクチャリングの採用は、開発期間の短縮と規制遵守の維持を目指すバイオ製薬会社、開発・製造受託機関（CDMO）、バイオテクノロジー新興企業によって先導されています。モノクローナル抗体、細胞・遺伝子治療薬、組換えタンパク質は、その複雑さと価値の高さから、デジタルトランスフォーメーションの恩恵を受ける主要な製品カテゴリーです。ワクチンとバイオシミラーの連続製造システムも、スループットと一貫性を最適化するためにデジタルツールを活用しています。

規制当局は、トレーサビリティを強化し、リアルタイムの品質保証を可能にするデジタル化の利点を認識しつつあります。このため、リアルタイム・リリース・テスト（RTRT）やクオリティ・バイ・デザイン（QbD）など、デジタル・インフラを活用することで容易に実施できる取り組みへの支持が高まっています。学術研究センターと技術ベンダーは、少量多品種生産に合わせた柔軟なモジュール式バイオ製造プラットフォームの構築に共同で取り組んでいます。その結果、上流の発酵・細胞培養から下流の精製・充填工程に至るまで、バリューチェーン全体がデジタル変革を遂げつつあります。

デジタル・バイオマニュファクチャリングの採用を加速させる主な成長要因とは？

デジタル・バイオマニュファクチャリング市場の成長は、柔軟でスケーラブルな生物製剤生産プラットフォームに対する需要の増加や、細胞治療や遺伝子治療などの先端治療の複雑化など、いくつかの要因によって牽引されています。プロセスの効率化、コスト削減、バッチの一貫性を重視する傾向が強まっており、AIを活用した予測制御システムやスマート分析ツールの導入がメーカーを後押ししています。シングルユース技術やモジュラー生産セットアップの採用も、これらのプラットフォームが本質的に適応可能でデータ中心であることから、デジタル統合に有利な条件を生み出しています。

個別化治療への移行、迅速なワクチン開発の必要性、生物製剤パイプラインの拡大といった最終用途の動向は、デジタルインフラへの投資を加速させています。これと並行して、継続的な製造、リアルタイムのデータ共有、QbDの実践に対する規制当局のサポートが、透明性と製品品質を高めるデジタルツールの導入をバイオメーカーに促しています。市場投入までの時間を短縮し、世界の需要の変動に対応し、オペレーションの回復力を向上させなければならないというプレッシャーが高まる中、デジタル・バイオマニュファクチャリングは次世代の医薬品生産戦略の要に急速になりつつあります。

セグメント

提供（ソフトウェア提供、ハードウェア提供）、機能（製品設計機能、プロセス最適化・分析機能、自動化・制御機能、その他機能）、用途（モノクローナル抗体用途、組換えホルモン・タンパク質用途、ワクチン用途、細胞ベースの生物製剤用途、遺伝子ベースの生物製剤用途）、最終用途（バイオ医薬品企業最終用途、学術・研究機関最終用途、CDMO・CRO最終用途）

調査対象企業の例（注目の41社）

  • 3M Company
  • ABB Ltd
  • Agilent Technologies Inc.
  • Aspen Technology Inc.
  • Atos SE
  • Cytiva（Danaher Corporation）
  • Dassault Systemes SE
  • Emerson Electric Co.
  • Eppendorf AG
  • FUJIFILM Diosynth Biotechnologies
  • GE HealthCare Technologies Inc.
  • Honeywell International Inc.
  • Immersciobio GmbH
  • Korber AG
  • Merck KGaA
  • Sartorius AG
  • Samsung Biologics Co. Ltd.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36708

Global Digital Biomanufacturing Market to Reach US$39.1 Billion by 2030

The global market for Digital Biomanufacturing estimated at US$18.2 Billion in the year 2024, is expected to reach US$39.1 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2024-2030. Software Offering, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$29.7 Billion by the end of the analysis period. Growth in the Hardware Offering segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.0 Billion While China is Forecast to Grow at 18.5% CAGR

The Digital Biomanufacturing market in the U.S. is estimated at US$5.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.4 Billion by the year 2030 trailing a CAGR of 18.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.8% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.8% CAGR.

Global Digital Biomanufacturing Market - Key Trends & Drivers Summarized

What Is Driving the Shift Toward Digitalization in Biomanufacturing?

Digital biomanufacturing represents the integration of data-driven technologies into biological production systems to enhance efficiency, flexibility, and quality across biopharmaceutical and biotech manufacturing processes. Traditionally reliant on batch-based, manual procedures, the biomanufacturing industry is now embracing digital tools such as advanced process control, predictive analytics, artificial intelligence, and machine learning to modernize and optimize operations. These technologies allow real-time monitoring, dynamic control of process parameters, and automated decision-making, which ultimately improves yield, reduces variability, and accelerates product release.

The push toward digitalization is particularly significant in the context of personalized medicine, gene therapies, and biosimilars, where production timelines and quality control are critical. In these high-stakes applications, digital tools ensure that manufacturing can adapt quickly to changing batch sizes, product types, and regulatory expectations. The ability to capture, model, and act on large datasets throughout upstream and downstream processes marks a critical turning point in transitioning biomanufacturing from reactive to predictive and adaptive operations.

How Are Advanced Technologies Powering the Digital Biomanufacturing Revolution?

The backbone of digital biomanufacturing lies in technologies like process analytical technology (PAT), digital twins, cloud computing, and AI-enabled bioprocess control systems. PAT tools enable continuous, in-line measurement of key quality attributes, allowing process parameters to be dynamically adjusted during production rather than relying on post-batch testing. Digital twins-virtual replicas of physical bioprocesses-can simulate scenarios, predict outcomes, and optimize system performance before implementation, reducing risks and minimizing costly downtime.

Machine learning algorithms are being applied to bioprocess data to forecast cell growth, product titers, and contamination risks, enabling preemptive interventions. Cloud-based platforms and edge computing facilitate real-time data sharing across facilities, making global collaboration and centralized control more accessible. Robotics and smart sensors are also enabling automation of tasks such as media preparation, cell line development, and purification, contributing to increased reproducibility, scalability, and compliance. These advancements are not just technological upgrades-they’re transforming how biologics are produced, validated, and distributed globally.

Which Applications and Stakeholders Are Driving Market Adoption?

The adoption of digital biomanufacturing is being spearheaded by biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and biotech startups seeking to accelerate development timelines and maintain regulatory compliance. Monoclonal antibodies, cell and gene therapies, and recombinant proteins are key product categories benefiting from digital transformation due to their complexity and high value. Continuous manufacturing systems for vaccines and biosimilars are also leveraging digital tools to optimize throughput and consistency.

Regulatory agencies are increasingly recognizing the benefits of digitalization in enhancing traceability and enabling real-time quality assurance. This has led to growing support for initiatives such as real-time release testing (RTRT) and Quality by Design (QbD), which are more readily implemented with digital infrastructure. Academic research centers and technology vendors are collaborating to build flexible, modular biomanufacturing platforms tailored to small-batch, high-mix production. As a result, the entire value chain-from upstream fermentation and cell culture to downstream purification and fill-finish operations-is undergoing a digital transformation.

What Are the Key Growth Drivers Accelerating Digital Biomanufacturing Adoption?

The growth in the digital biomanufacturing market is driven by several factors, including the increasing demand for flexible, scalable biologics production platforms and the rising complexity of advanced therapies such as cell and gene treatments. The growing emphasis on process efficiency, cost reduction, and batch consistency is encouraging manufacturers to deploy AI-powered predictive control systems and smart analytics tools. The adoption of single-use technologies and modular production setups is also creating favorable conditions for digital integration, as these platforms are inherently adaptable and data-centric.

End-use trends such as the shift to personalized therapies, the need for rapid vaccine development, and the expansion of biologics pipelines are accelerating investment in digital infrastructure. In parallel, regulatory support for continuous manufacturing, real-time data sharing, and QbD practices is pushing biomanufacturers to embrace digital tools that enhance transparency and product quality. With increasing pressure to reduce time-to-market, meet global demand variability, and improve operational resilience, digital biomanufacturing is rapidly becoming a cornerstone of next-generation pharmaceutical production strategies.

SCOPE OF STUDY:

The report analyzes the Digital Biomanufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Software Offering, Hardware Offering); Functionality (Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality, Other Functionalities); Application (Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application, Vaccines Application, Cellular-based Biologics Application, Gene-based Biologics Application); End-Use (Biopharma Companies End-Use, Academic & Research Institutes End-Use, CDMOs & CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • 3M Company
  • ABB Ltd
  • Agilent Technologies Inc.
  • Aspen Technology Inc.
  • Atos SE
  • Cytiva (Danaher Corporation)
  • Dassault Systemes SE
  • Emerson Electric Co.
  • Eppendorf AG
  • FUJIFILM Diosynth Biotechnologies
  • GE HealthCare Technologies Inc.
  • Honeywell International Inc.
  • Immersciobio GmbH
  • Korber AG
  • Merck KGaA
  • Sartorius AG
  • Samsung Biologics Co. Ltd.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Digital Biomanufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise of Precision Biologics and Personalized Therapies Propels Demand for Digital Biomanufacturing Tools
    • Integration of AI and Machine Learning in Bioprocess Optimization Throws Spotlight on Predictive Production Models
    • OEM Adoption of Digital Twins for Bioreactor Monitoring Enhances Yield and Quality Control
    • Expansion of Smart Sensors and Process Analytics Strengthens Real-Time Bioprocess Adjustments
    • Focus on Reducing Batch Failures Drives Automation and Closed-Loop Control in Biologics Manufacturing
    • Increased Biopharma Investments in Industry 4.0 Strategies Accelerate Smart Factory Implementations
    • Growing Complexity in Cell and Gene Therapy Production Fuels Need for High-Precision Digital Control
    • Use of Cloud-Based Data Lakes in Biomanufacturing Supports Centralized Analytics and Multi-Site Visibility
    • Integration of PAT (Process Analytical Technology) Frameworks Accelerates FDA-Ready Compliance
    • Global Biotech Capacity Expansion Promotes Adoption of Scalable Digital Manufacturing Platforms
    • Rising Cost Pressures in Biosimilars Manufacturing Spur Operational Efficiency via Digitalization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Digital Biomanufacturing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Digital Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Digital Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Software Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Software Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Hardware Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Hardware Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cellular-based Biologics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Cellular-based Biologics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Gene-based Biologics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Gene-based Biologics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Monoclonal Antibodies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Monoclonal Antibodies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Recombinant Hormones / Proteins Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Recombinant Hormones / Proteins Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for CDMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for CDMOs & CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Product Design Functionality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Product Design Functionality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Process Optimization & Analytics Functionality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Process Optimization & Analytics Functionality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Automation & Control Functionality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Automation & Control Functionality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Other Functionalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Other Functionalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • JAPAN
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • CHINA
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • EUROPE
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Digital Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • FRANCE
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • GERMANY
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • UNITED KINGDOM
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • SPAIN
    • TABLE 106: Spain Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Spain 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 108: Spain Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Spain 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 112: Spain Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Spain 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • RUSSIA
    • TABLE 114: Russia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Russia 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 116: Russia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Russia 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 118: Russia Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Russia 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 120: Russia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Russia 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of Europe 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 126: Rest of Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Europe 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 132: Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 136: Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 138: Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • AUSTRALIA
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 140: Australia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Australia 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 142: Australia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Australia 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 144: Australia Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Australia 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 146: Australia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Australia 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • INDIA
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 148: India Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 149: India 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 150: India Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 151: India 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 152: India Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: India 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 154: India Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 155: India 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 156: South Korea Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 157: South Korea 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 158: South Korea Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: South Korea 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 160: South Korea Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 161: South Korea 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 162: South Korea Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 163: South Korea 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 164: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 166: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Rest of Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 168: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 169: Rest of Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 170: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Asia-Pacific 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • LATIN AMERICA
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 172: Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 173: Latin America 6-Year Perspective for Digital Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 174: Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Latin America 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 176: Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Latin America 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 178: Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Latin America 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 180: Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Latin America 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 182: Argentina Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Argentina 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 184: Argentina Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Argentina 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 186: Argentina Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Argentina 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 188: Argentina Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Argentina 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • BRAZIL
    • TABLE 190: Brazil Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 191: Brazil 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 192: Brazil Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 193: Brazil 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 194: Brazil Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Brazil 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 196: Brazil Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Brazil 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • MEXICO
    • TABLE 198: Mexico Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Mexico 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 200: Mexico Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Mexico 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 202: Mexico Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Mexico 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 204: Mexico Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Mexico 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 206: Rest of Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Latin America 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 208: Rest of Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 209: Rest of Latin America 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 210: Rest of Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 211: Rest of Latin America 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 212: Rest of Latin America Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Latin America 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • MIDDLE EAST
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 214: Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 215: Middle East 6-Year Perspective for Digital Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 216: Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 217: Middle East 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 218: Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Middle East 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 220: Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 221: Middle East 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 222: Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 223: Middle East 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • IRAN
    • TABLE 224: Iran Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Iran 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 226: Iran Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 227: Iran 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 228: Iran Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 229: Iran 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 230: Iran Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Iran 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • ISRAEL
    • TABLE 232: Israel Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 233: Israel 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 234: Israel Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 235: Israel 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 236: Israel Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Israel 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 238: Israel Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 239: Israel 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 240: Saudi Arabia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 241: Saudi Arabia 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 242: Saudi Arabia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Saudi Arabia 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 244: Saudi Arabia Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 245: Saudi Arabia 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 246: Saudi Arabia Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 247: Saudi Arabia 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 248: UAE Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: UAE 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 250: UAE Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 251: UAE 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 252: UAE Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 253: UAE 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 254: UAE Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: UAE 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 256: Rest of Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 257: Rest of Middle East 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 258: Rest of Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 259: Rest of Middle East 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 260: Rest of Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Middle East 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 262: Rest of Middle East Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 263: Rest of Middle East 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030
  • AFRICA
    • Digital Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 264: Africa Recent Past, Current & Future Analysis for Digital Biomanufacturing by Offering - Software Offering and Hardware Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 265: Africa 6-Year Perspective for Digital Biomanufacturing by Offering - Percentage Breakdown of Value Sales for Software Offering and Hardware Offering for the Years 2025 & 2030
    • TABLE 266: Africa Recent Past, Current & Future Analysis for Digital Biomanufacturing by Application - Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Africa 6-Year Perspective for Digital Biomanufacturing by Application - Percentage Breakdown of Value Sales for Cellular-based Biologics Application, Gene-based Biologics Application, Monoclonal Antibodies Application, Recombinant Hormones / Proteins Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 268: Africa Recent Past, Current & Future Analysis for Digital Biomanufacturing by End-Use - Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 269: Africa 6-Year Perspective for Digital Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Academic & Research Institutes End-Use and CDMOs & CROs End-Use for the Years 2025 & 2030
    • TABLE 270: Africa Recent Past, Current & Future Analysis for Digital Biomanufacturing by Functionality - Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 271: Africa 6-Year Perspective for Digital Biomanufacturing by Functionality - Percentage Breakdown of Value Sales for Product Design Functionality, Process Optimization & Analytics Functionality, Automation & Control Functionality and Other Functionalities for the Years 2025 & 2030

IV. COMPETITION